Kwai-Ming J. Cheung - Concepedia

Author

Kwai-Ming J. Cheung

Institute of Cancer Research

Also Known As

Cheung, Kwai-Ming, Cheung, Kwai-Ming J., K.J. Cheung, Kwai-Ming Cheung, Kwai-Ming J. Cheung, Kwai‐Ming Cheung

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

Institute of Cancer Research Cancer Research UK Breast Cancer Now University of Cambridge

About

Kwai-Ming J. Cheung is an author at Institute of Cancer Research specializing in natural sciences, biochemistry, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	9	9	628
2	Biochemistry	9	9	628
3	Medicine	7	7	595
4	Biomolecular Engineering	4	4	173
5	Engineering	3	3	52

Kwai-Ming J. Cheung

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis Suzanne A. Eccles, Andy Massey, Florence I. Raynaud, Cancer Research	2008	469
4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer Paul A. Brough, Wynne Aherne, Xavier Barril, Journal of Medicinal Chemistry	2007	442
The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors Kwai-Ming J. Cheung, Thomas P. Matthews, Karen James, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryDrug TargetBiochemistryHsp90 InhibitorsNatural Sciences	2005	219
Inhibition of the heat shock protein 90 molecular chaperone <i>in vitro</i> and <i>in vivo</i> by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues Swee Y. Sharp, Chrisostomos Prodromou, Kathy Boxall, Molecular Cancer Therapeutics	2007	142
<i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors Swee Y. Sharp, Kathy Boxall, Martin Rowlands, Cancer Research	2007	111
Discovery of 4-Amino-1-(7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt) Tatiana McHardy, John Caldwell, Kwai-Ming J. Cheung, Journal of Medicinal Chemistry Drug TargetRelated Kinase PkaPharmacotherapyChemical BiologyPharmaceutical Chemistry	2010	83
Structure-Based Design of Orally Bioavailable 1<i>H</i>-Pyrrolo[3,2-<i>c</i>]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1) Sébastien Naud, Isaac M. Westwood, Amir Faisal, Journal of Medicinal Chemistry Pharmaceutical ScienceMolecular BiologyMps1 InhibitionPharmaceutical ChemistrySelective Mps1 Inhibitors	2013	79
Achieving <i>In Vivo</i> Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders Benjamin R. Bellenie, Kwai-Ming J. Cheung, Ana Varela, Journal of Medicinal Chemistry	2020	72
Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization Daniel K. Whelligan, Savade Solanki, Dawn Taylor, Journal of Medicinal Chemistry Drug TargetUnusual Inactive ConformationKinase InhibitorsMolecular BiologyChemical Biology	2010	70
A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death Jonathan Mannion, Valentina Gifford, Benjamin R. Bellenie, Immunity	2024	63

Page 1